Investigational drug · Phase 2
MORF-057
Also called: zotemtegrast, LY4268989
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
8
Any phase or sponsor naming "MORF-057"
First trial start
2022
Nov 21, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MORF-057", any sponsor or status.
Conditions studied
As listed on its trial records.
- Inflammatory Bowel Diseases
- Crohn's Disease
- Ulcerative Colitis (UC)
- Ulcerative Colitis, Active Moderate
- Ulcerative Colitis, Active Severe
- Ulcerative Colitis
- Colitis, Ulcerative
Approved drugs for the same conditions: Crohn's disease · Ulcerative colitis · Immunology and inflammation · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "MORF-057" as an intervention, largest first.
- LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07415044 · 1,431 participants (planned) · Start Mar 26, 2026 · Primary completion Jun 2030
Drug: LY4268989; Placebo · For: Ulcerative Colitis (UC); Ulcerative Colitis, Active Moderate; Ulcerative Colitis, Active Severe
Sites: Phoenix, Arizona; Scottsdale, Arizona; Anaheim, California · 258 sites in all
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Industry
NCT06226883 · 385 participants (planned) · Start Jul 18, 2024 · Primary completion Sep 2028
Drug: Placebo; MORF-057 · For: Inflammatory Bowel Diseases; Crohn's Disease
Sites: Lancaster, California; San Diego, California; Colorado Springs, Colorado · 224 sites in all
- A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UCPivotal-lookingCompleted
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Industry
NCT05611671 · 280 participants · Start Nov 21, 2022 · Primary completion Nov 28, 2024
Drug: MORF-057; Placebo · For: Inflammatory Bowel Diseases; Colitis, Ulcerative
Sites: Sun City, Arizona; Lancaster, California; Los Angeles, California · 102 sites in all
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07186101 · 252 participants (planned) · Start Nov 10, 2025 · Primary completion May 2027
Drug: LY4268989; Mirikizumab and 1 more · For: Ulcerative Colitis
Sites: Scottsdale, Arizona; Anaheim, California; Lancaster, California · 147 sites in all
- A Study of LY4268989 (MORF-057) in Healthy ParticipantsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06964776 · 144 participants · Start May 1, 2025 · Primary completion Feb 17, 2026
Drug: LY4268989; Placebo and 2 more · For: Healthy
Sites: Anaheim, California
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Industry
NCT04580745 · 67 participants · Start Sep 23, 2020 · Primary completion Mar 31, 2021
Drug: MORF-057; Placebo for MORF-057 · For: Healthy Volunteers
Sites: Cincinnati, Ohio
Eli Lilly and CompanyEli Lilly (LLY)
NCT07707375 · 50 participants · Start Jul 20, 2026 · Primary completion Oct 8, 2026
Drug: LY4268989 · For: Healthy
Sites: Daytona Beach, Florida
- A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UCCompleted
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Industry
NCT05291689 · 39 participants · Start Apr 13, 2022 · Primary completion Oct 18, 2023
Drug: MORF-057 · For: Inflammatory Bowel Diseases; Colitis, Ulcerative
Sites: Tampa, Florida; Lafayette, Louisiana; Freehold, New Jersey · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis.
Sands BE, Schreiber S, Danese S, et al. · Clin Gastroenterol Hepatol 2026
- Gut-directed therapeutics in inflammatory bowel disease.
Kratschmer C, Curiel DT, Ciorba MA · Curr Opin Gastroenterol 2025
Also in development for Inflammatory Bowel Diseases
- SPY001SPY001-001Phase 22 trials
Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis
- SPY002SPY002-091Phase 22 trials
Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis
- SPY003SPY003-207Phase 22 trials
Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis
- ATH-063Phase 21 trial
Athos Therapeutics Inc · Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.